Objective-Mounting evidence links osteoprotegerin with cardiovascular disease. Elevated serum and aortic tissue osteoprotegerin are associated with the presence and growth of abdominal aortic aneurysm in humans; however, a role for osteoprotegerin in abdominal aortic aneurysm pathogenesis remains to be shown. We examined the functional significance of osteoprotegerin in aortic aneurysm using an Opg-deficient mouse model and in vitro investigations. Approach and Results-Homozygous deletion of Opg in apolipoprotein E-deficient mice (ApoE −/− Opg −/− ) inhibited angiotensin II-induced aortic dilatation. Survival free from aortic rupture was increased from 67% in ApoE −/− Opg +/+ controls to 94% in ApoE −/− Opg −/− mice (P=0.040). Serum concentrations of proinflammatory cytokines/chemokines, and aortic expression for cathepsin S (CTSS), matrix metalloproteinase 2, and matrix metalloproteinase 9 after 7 days (early-phase) of angiotensin II infusion were significantly reduced in ApoE −/− Opg −/− mice compared with ApoE −/− Opg +/+ controls. In addition, aortic expression of markers for an inflammatory phenotype in aortic vascular smooth muscle cells in response to early-phase of angiotensin II infusion was significantly lower in Opg-deficient mice. In vitro, human abdominal aortic aneurysm vascular smooth muscle cells produced more CTSS and exhibited increased CTSS-derived elastolytic activity than healthy aortic vascular smooth muscle cells, whereas recombinant human osteoprotegerin stimulated CTSS-dependent elastase activity in aortic vascular smooth muscle cells. Conclusions-These findings support a role for osteoprotegerin in aortic aneurysm through upregulation of CTSS, matrix metalloproteinase 2, and matrix metalloproteinase 9 within the aorta, promoting an inflammatory phenotype in aortic vascular smooth muscle cells in response to angiotensin II. (Arterioscler Thromb Vasc Biol. 2014;34:2609-2616.)
A bdominal aortic aneurysm (AAA) is the degenerative weakening and dilatation of the abdominal aorta. The main complication of AAA is aortic rupture, which is associated with a mortality of ≈80%. 1 There is no currently accepted drug treatment to limit AAA rupture. 2 Despite advances in our understanding of its pathophysiology, precise mechanisms involved in AAA are uncertain. It is commonly accepted that an unknown inciting event results in injury of the aortic wall and recruitment of leukocytes to the site. Release of proteolytic enzymes from these cells and resident vascular cells (aortic smooth muscle cells [AoSMC] ) in response to local proinflammatory cytokine production contributes to the destruction of the extracellular matrix (ECM). Apoptosis of AoSMC results in the loss of cells primarily responsible for the synthesis of ECM proteins, which limits ECM repair. 3 Osteoprotegerin is a secreted glycoprotein member of the tumor necrosis factor receptor superfamily (TNFRSF11B). Since its initial discovery as a key regulator of bone metabolism, osteoprotegerin has attracted interest for its role in vascular disease. 4 High concentrations of serum osteoprotegerin have been identified as a marker and risk factor for cardiovascular disease, as well as a predictor for future incident cardiovascular events and mortality. [5] [6] [7] [8] In line with this, we have reported previously that patients with AAA have elevated aortic and serum osteoprotegerin concentrations that are positively associated with aneurysm diameter and growth 9, 10 and independently associated with AAA after adjusting for other risk factors such as coronary heart disease. 11 In vitro, osteoprotegerin stimulates production of elastolytic enzymes in human monocyte/macrophages and AoSMC 9,10 and promotes an aneurysm phenotype in healthy AoSMC through limiting cell proliferation and inducing apoptosis. 10 The in vivo role of osteoprotegerin in AAA pathogenesis remains unclear.
We positively correlated human AAA concentrations of osteoprotegerin with aneurysm diameter in a recent study. 9 Historically, matrix metalloproteinases (MMPs) have been the main proteolytic enzymes implicated in ECM degradation in AAA. 12 More recently, other proteolytic enzymes such as the cysteine cathepsin proteases have been implicated in AAA pathogenesis. 12, 13 Cathepsin S (CTSS) is a potent elastolytic/collagenolytic protease for which elevated expression and activity have been demonstrated in human AAA tissue. 14 Plasma levels of total, pro-and active CTSS have been positively associated with aortic diameter in patients with AAA. 15, 16 Experimentally, aortic aneurysm induction in mice is dependent on AoSMC expression of CTSS 17 and inhibited by Ctss deficiency. 18 The aim of this study was to assess the effect of Opg deficiency on aortic aneurysm development in a mouse model. Using an Opg-deficient angiotensin II (AngII)-infused apolipoprotein E-deficient (ApoE −/− ) mouse model, we provide in vivo evidence for the involvement of osteoprotegerin in structural (ECM) and cellular (AoSMC) destabilization within the aortic wall. A novel functional association between osteoprotegerin and CTSS is reported.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Opg Deficiency Inhibits AngII-Induced Aortic Dilatation and Rupture in a Mouse Model of Aortic Aneurysm
Aortic and serum osteoprotegerin concentrations are elevated in patients with AAA and positively associated with AAA expansion in humans. 9, 10 The in vivo importance of osteoprotegerin in the development of aortic aneurysm was investigated in Opgdeficient mice infused with AngII. A preliminary study using C57BL/6 (ApoE +/+ ) mice demonstrated that Opg deficiency limited AngII-induced aortic dilatation in these mice compared with wild-type controls, most significantly within the aortic arch and thoracic aorta ( Table I in the online-only Data Supplement) . We subsequently investigated the effect of Opg deficiency on AngII-induced aortic aneurysm in the ApoE −/− mouse model. A time-dependent increase in suprarenal aorta diameter in response to AngII infusion during the 28-day experimental period was observed by ultrasound in both ApoE −/− Opg +/+ control (P<0.001) and ApoE −/− Opg −/− experimental (P<0.001) mice ( Figure 1A ). The rate of suprarenal aorta expansion in response to AngII was, however, markedly less in ApoE −/− Opg −/− mice (P<0.001; Figure 1A ). Aortas from all mice were harvested after fatality or euthanization at study end and regional maximum aortic diameters determined by morphometric analysis ( Figure II in the online-only Data Supplement). ApoE −/− Opg −/− mice exhibited significantly smaller median maximum diameter of aortic arch, thoracic aorta, suprarenal aorta, and infrarenal aorta compared with ApoE −/− Opg +/+ controls ( Figure 1B ; Figure III in the online-only Data Supplement). An important complication associated with the infusion of AngII in ApoE −/− mice is fatality because of aortic rupture. Opg deficiency markedly improved survival from aortic rupture, increasing survival rate from 67% in ApoE −/− Opg +/+ mice to 94% in ApoE −/− Opg −/− mice (P=0.040; Figure 1C ).
Effect of Opg Deficiency on AngII-Induced Aortic Dilatation Is Blood Pressure Independent and Associated With a Reduced Initial Inflammatory Response to AngII
Infusion of AngII in ApoE −/− mice resulted in a time-dependent increase in blood pressure during the 28-day infusion period (P<0.001; Table 1 ). The increase in blood pressure induced by AngII was not affected by Opg deficiency. Median systolic, diastolic, and mean arterial blood pressures obtained at baseline (day 0), day 14, and day 28 remained comparable between ApoE −/− Opg +/+ and ApoE −/− Opg −/− mice ( Table 1 ). The concentration of a range of cytokines and chemokines was measured in the serum of ApoE −/− Opg +/+ and ApoE −/− Opg −/− mice during a 7-day infusion of AngII (Table 2 ). Median concentrations of interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-6, IL-12, IL-17, monocyte chemotactic protein (MCP)-1, tumor necrosis factor (TNF)-α, macrophage inflammatory protein-1α, granulocytemacrophage colony-stimulating factor, and regulated on activation, normal T cell expressed and secreted were significantly increased in ApoE −/− Opg +/+ control mice after 7 days of AngII infusion compared with baseline concentrations ( Table 2 ). In contrast, levels of these cytokines were not markedly elevated in serum from ApoE −/− Opg −/− mice after the same period of AngII infusion ( Table 2) . Notably, baseline concentrations of IL-6, MCP-1, and TNFα were significantly lower in ApoE −/− Opg −/− mice compared with ApoE −/− Opg +/+ controls, and median foldincrease in all markers other than IL-1β and MCP-1 in response to AngII infusion remained significantly lower in ApoE −/− Opg −/− mice ( Table 2 ). The presence of MOMA-2 (macrophage and monocyte antibody)-positive (monocyte/macrophage) cells was demonstrated within the suprarenal aortic adventitia of AngII-infused ApoE −/− Opg −/− mice at 28 days ( Figure IV 
Reduced Proteolysis in Aortas of AngII-Infused ApoE −/− Opg −/− Mice
Based on reported associations between osteoprotegerin and metallo/cysteine proteinases in promoting AAA, 9, 10, 19 we examined MMP2, MMP9, and CTSS expression within aortas of ApoE −/− Opg +/+ (n=6) and ApoE −/− Opg −/− (n=6) mice after 7 days of AngII infusion. Median relative expression of Mmp2, Mmp9, and Ctss within the aortas of ApoE −/− Opg −/− mice was reduced by 2-, 3-, and 7-fold, respectively, compared with ApoE −/− Opg +/+ controls ( translated to reduced aortic levels of these proteases. Median levels of MMP2 and MMP9 (P=0.001, P=0.028; Figure 2A ; Figure V in the online-only Data Supplement) and CTSS (P=0.002; Figure 2B ) were significantly lower within aortic tissue from ApoE −/− Opg −/− mice compared with ApoE −/− Opg +/+ controls after the 7-day AngII infusion period. Interestingly, median activity of CTSS within aortic tissue of ApoE −/− Opg −/− mice (n=16), measured using a substrate-specific assay, was 2-fold lower than in ApoE −/− Opg +/+ controls (n=12) after 28 days of AngII infusion (3.27, 2.17-4.44, versus 6.89, 5.02-8.99 Δfluorescence unit/min per microgram protein; P=0.009).
Elevated Production of CTSS by Human AAA Vascular Smooth Muscle Cells and Stimulation of CTSS-Derived Elastolytic Activity in Healthy AoSMC by Osteoprotegerin In Vitro
Serum concentrations of osteoprotegerin and CTSS are elevated in patients with AAA and positively associated with aneurysm diameter. 10, 11, 15, 16 Production of osteoprotegerin and CTSS within AAA tissue may contribute to circulating levels of these proteins in patients with AAA. We have previously demonstrated a positive correlation between tissue concentrations of osteoprotegerin and CTSS within human AAA biopsies, and that osteoprotegerin upregulates CTSS in healthy human AoSMC in vitro. 9 The production of CTSS by smooth muscle cells isolated from aortic aneurysm tissue (AASMCs) compared with AoSMC and the ability of osteoprotegerin to stimulate CTSSdependent elastolytic activity in AoSMC were assessed in vitro. The concentration of total CTSS in supernatants (secreted) and cell lysates (cellular) from human AASMC (n=6 cultures) and AoSMC (n=6 cultures) was determined by ELISA. The median concentration of secreted CTSS from AASMC was 5-fold higher than that of AoSMC (P=0.025; Figure 3A ). Similarly, median cellular CTSS was 1.6-fold higher in AASMC than that of AoSMC (P=0.002; Figure 3A ). CTSS-derived elastase activity in AoSMC and AASMC was measured using a commercial elastin degradation assay that we initially evaluated using AngII-activated AoSMC ( Figure VI in the online-only Data Supplement). Cells were coincubated with the CTSS inhibitor Z-FL-COCHO (20 nmol/L) to assess the contribution of CTSS to total elastase activity ( Figure VI in the online-only Data Supplement). CTSS-derived elastase activity was 3-fold higher in unstimulated AASMC than in unstimulated healthy AoSMC (P=0.002; Figure 3B ). Incubation of AASMC in the presence of recombinant human osteoprotegerin (50 nmol/L; n=6) for 36 hours did not significantly affect elastase activity in these cells. In contrast, the median level of elastase activity in AoSMC cultured in the presence of recombinant human osteoprotegerin was 4.5-fold higher than that measured in control AoSMC (P=0.002; Figure 3B ). In the presence of the CTSS inhibitor, median elastase activity stimulated by recombinant human osteoprotegerin, while remaining elevated compared with control cultures, was reduced in both AASMC and AoSMC by 1.5-fold (P=0.004) and 2-fold (P=0.002), respectively ( Figure 3B ).
Differential Expression of mRNA for Factors Regulating AoSMC Function Within Aortas of AngII-Infused ApoE −/− Opg +/+ and ApoE −/− Opg −/− Mice
The contribution of AoSMC loss to structural degeneration of the aortic media has been suggested through studies in human AAA tissue and animals models of aortic aneurysm. 18, 20, 21 We have shown previously the ability of osteoprotegerin to limit 
Discussion
The presence and growth of AAA in humans are independently associated with serum concentrations of osteoprotegerin. 10, 11, 22 Expression of osteoprotegerin within AAA biopsies is positively correlated with AAA diameter. 8, 9 These association studies implicate osteoprotegerin in AAA; however, previously in vivo evidence for a role of osteoprotegerin in AAA pathogenesis has been absent. Here, we report that Opg deficiency in the ApoE −/− mouse limits AngII-induced aortic dilatation and rupture and present additional in vivo and in vitro data to support a contributing role for osteoprotegerin in aortic wall weakening. Maximum aortic diameter is commonly presented as the primary outcome measure in experimental AAA studies. [23] [24] [25] Aneurysm diameter is an important clinical indicator of rupture risk for AAA in humans and routinely used in selected patients for surgical intervention. 2 Ultimately any medical treatment for aortic aneurysm aims to limit the main complication of aneurysm rupture. We used the AngII-infused ApoE −/− mouse model of aortic aneurysm in which aortic dilatation results from breaks in medial elastic lamellae and bleeding into the artery wall, a process that leads to acute aortic rupture in ≈30% of mice. 26 This model allowed the assessment of both survival free from aortic rupture and maximum aortic diameter. Aortic diameter was assessed by 2 techniques, namely ultrasound performed in live mice and morphometry of harvested aortas. Opg deficiency consistently limited AngII-induced aortic dilatation and rupture as assessed by all these outcome measures. The 5-fold lower incidence of fatality because of aortic rupture in Opg-deficient ApoE −/− mice was particularly noteworthy. These findings suggest the importance of osteoprotegerin in promoting aortic wall degeneration in this model.
Consistent with previous reports, we observed a timedependent increase in blood pressure in ApoE −/− Opg +/+ mice. 23, 27 Higher levels of serum and aortic osteoprotegerin are measured in AngII-infused ApoE −/− Opg +/+ mice that develop more severe aortic dilatations, 19, 28 indicating a potential link between elevated blood pressure and increased osteoprotegerin contributing to aneurysm formation in this model. Previous studies however suggest that AngII induces aortic aneurysm by mechanisms independent of blood pressure elevation. 23, 29 Opg deficiency did not affect the hypertensive response to AngII infusion suggesting that Opg promotes aortic aneurysm by blood pressure-independent mechanisms.
Leukocyte infiltration of the aortic wall is a prominent early response to AngII infusion that has been implicated strongly in aneurysm formation in this model. 24, 26, 33 Human and animal studies suggest that cytokines and chemokines, such as TNFα, IL-6, and MCP-1, play a key role in aortic leukocyte recruitment and activation. 30, 31 In the current study, a lower incidence of AngII-induced aortic dilatation in Opg-deficient ApoE −/− mice corresponded with decreased levels of a range of circulating proinflammatory cytokine and chemokines. The most notable of these were TNFα, IL-6, and MCP-1. Baseline concentrations of these proteins were significantly lower in ApoE −/− Opg −/− mice compared with controls. Importantly, the concentrations of these proteins did not significantly increase in ApoE −/− Opg −/− mice after AngII infusion unlike the situation in ApoE −/− Opg +/+ controls in which a significant increase in the concentrations of all 3 proteins was identified. These findings suggest that Opg deficiency acted to suppress the inflammatory response to AngII infusion.
Infusion of AngII results in the overexpression of osteoprotegerin, CTSS, MMP2, and MMP9 in the aorta of ApoE −/− mice. 19, 28 In the present study, although detection of MOMA-2 in suprarenal aorta of ApoE −/− Opg −/− mice indicated the presence of monocyte/macrophages within the aortic wall, reduced aortic dilatation in these mice was associated with downregulation of aortic CTSS, MMP2, and MMP9. A recent study reported that reduced aortic aneurysm in Ctss-null AngII-infused ApoE −/− mice was associated with decreased aortic activity of MMP2 and MMP9, implicating CTSS in the regulation of these proteases. 18 These findings suggest a functional association between osteoprotegerin, CTSS, MMP2, and MMP9 in aortic aneurysm. Indeed, aortic concentrations of osteoprotegerin correlate with those of CTSS, MMP2, and MMP9, and increasing infrarenal aorta diameter in patients with AAA. 9 Vascular smooth muscle cells have been identified as a major source of osteoprotegerin within human AAA tissue, 9 and MMP production in healthy AoSMC is stimulated by osteoprotegerin in vitro. 10 Here, we show AASMCs also produce large quantities of CTSS in vitro. Interestingly, incubation of AASMC in the presence of osteoprotegerin had no significant effect to increase CTSS in these cells. Cellular and secreted levels of osteoprotegerin 10 and CTSS are markedly elevated in AASMC in vitro compared with healthy human AoSMC. Thus, it is plausible that exogenous osteoprotegerin had little effect on already maximally stimulated cells from advanced-stage AAA. Nonetheless, our observation that osteoprotegerin stimulated CTSS, and CTSS-derived elastase activity in healthy human AoSMC in vitro provides evidence of an association between osteoprotegerin and upregulation of protease activity within the aneurysmal aortic wall.
Previous human and animal studies suggest that AASMCs exhibit a phenotype that favors aortic ECM degeneration. 18, 20, 25, 32, 33 In particular, they have reduced ability to proliferate, increased apoptosis tendency, and promoted inflammation and matrix degradation. 18, 20, 25, 32, 33 Exposure of AoSMC to osteoprotegerin in vitro results in inhibition of cell growth and induction of apoptosis. 10 Dedifferentiation (phenotype modulation) of vascular smooth muscle cells to an inflammatory phenotype in response to vascular injury involves downregulation of genes involved in the regulation and modulation of smooth muscle contraction. 34 Phenotypic modulation is associated with reduction in mitogen-activated protein kinase (MAPK)1/3 activation resulting in decreased myosin light chain phosphorylation and loss of contractile properties. 35 Calponin 1 facilitates signal transduction by MAPK1/3, 36 and Cnn1 deletion in differentiated vascular smooth muscle cells results in impaired MAPK1/3 activity and cell contractility. 37 Evidence also suggests that MAPK1/3 possesses actin-binding properties and that an intact actin cytoskeleton, degraded during apoptosis, is required for MAPK1/3 signaling. 38 Our comparison of selected genes in the aortas of ApoE −/− Opg −/− and ApoE −/− Opg +/+ mice after 7 days of AngII infusion showed a 10-and 7-fold greater expression of Cnn1 and Mapk1/3, respectively, within the aortas of ApoE −/− Opg −/− mice. These findings suggest that Opg deficiency promotes a more stable AoSMC phenotype within the aortic wall, a theory supported by the 2-fold lower expression ratio of the apoptosis markers Bax and Bcl2 also observed within aortas of ApoE −/− Opg −/− mice. Thus, it is postulated that the inhibition of aortic dilatation and rupture in ApoE −/− Opg −/− mice is contributed to by an AoSMC phenotype that is less responsive to functional change after AngII infusion.
Activation of PPARγ downregulates AngII type 1 receptor and osteoprotegerin expression in vascular smooth muscle cells, 39, 40 whereas its own expression is negatively regulated by AngII via activation of AngII type 1 receptor. 41, 42 We have previously shown that PPARγ activation blocks osteoprotegerininduced upregulation of AngII type 1 receptor in human AAA explant and AoSMC. 19 A protective role for PPARγ in aortic aneurysm has been demonstrated recently in 2 independent mouse models of AAA incorporating vascular smooth muscle cell-selective Pparg deletion. 17, 43 Importantly, the absence of vascular smooth muscle cell PPARγ rendered mice more susceptible to CTSS-associated degeneration of medial elastin. 17 PPARγ binds to a peroxisome proliferator-activated receptor response element upstream of the CTSS gene in AoSMC and knockdown and overexpression of PPARγ results in the increase and decrease, respectively, of CTSS mRNA and activity. 17 Here, we report increased expression of Pparg and decreased expression of Ctss in aortas of ApoE −/− Opg −/− mice associated with reduced incidence of AngII-induced aortic aneurysm. The upregulation of PPARγ in Opg-deficient mice may act to negatively regulate AngII type 1 receptor and CTSS in AoSMC and contribute to the relative resistance of these mice to AngII-induced aortic aneurysm. AngII-induced aortic aneurysm in ApoE −/− mice involves the activation of NFκB with increases in both p52 and p65 NFκB subunits within the aortic wall. 41 The 3-fold increase in NFκB mRNA observed within aortas of ApoE −/− Opg −/− mice seems inconsistent with the inhibition of AngII-induced aortic dilatation in these mice. An explanation might be in the concurrent increases of aortic Mapk1/3 and Pparg reported above. Phosphorylation of PPARγ via active MAPK1/3 leads to the physical association of PPARγ with the NFκB p65 subunit and inhibition of NFκB activity. 44 It is possible that the increase in Nfkb expression in Opg-deficient mice is a compensatory response. However, why Nfkb expression is increased in aortas of AngII-infused ApoE −/− Opg −/− mice compared with ApoE −/− Opg +/+ controls remains to be elucidated.
Several study limitations are acknowledged. First, only the AngII-induced mouse model was used to examine the effect of Opg deficiency on aneurysm formation. This model was used as it simulates both aortic expansion and rupture seen in human aortic aneurysm. We have also previously linked osteoprotegerin and AngII in aortic aneurysm pathogenesis. 19, 28 Examination of the effect of osteoprotegerin in other mouse models is needed. Second, we focused on CTSS in the current study as a potential effector of osteoprotegerin in promoting aortic aneurysm based on previous studies implicating it in aneurysm pathogenesis. 17, 18 Other cysteine protease cathepsins (eg, B, K, and L) and the endogenous cathepsin inhibitor, cystatin C, have also been implicated in experimental and human AAA. 13 Whether the inhibition of aortic aneurysm resulting from osteoprotegerin deficiency involved modulation of these proteases was not investigated. Finally, the mechanistic focus of the present study was on osteoprotegerin-mediated phenotype switching in AoSMC. We did not study the potential immune-regulatory actions of osteoprotegerin and CTSS that may contribute to human aortic aneurysm. 45, 46 Expression of osteoprotegerin and CTSS in advanced-stage human AAA is not limited to vascular cells, but present also in leukocytes, lymphocytes, and plasma cells. 9, 10, 47 The effect of Opg deficiency on these cells requires further study.
In summary, the current study suggests a role for osteoprotegerin in aortic aneurysm formation and rupture. In vitro, osteoprotegerin stimulated CTSS and CTSS-derived elastase activity in AoSMC. In vivo, Opg deficiency was associated with downregulation of CTSS, MMP2, and MMP9 within aortas of AngII-infused ApoE −/− mice and an aortic gene expression profile suggesting AoSMC differentiation and viability. It is postulated that Opg deficiency reduced aortic proteolysis and stimulation of an AoSMC inflammatory phenotype in response to AngII, thus reducing aortic dilatation and rupture. 
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